ArticleMolecular cancer research : MCR2021
Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model.
Rajaa El Meskini, Devon Atkinson, Alan Kulaga, Abdalla Abdelmaksoud, Michelle Gumprecht, Nathan Pate, Susana Hayes, Michael Oberst, Ian M Kaplan, Patrick Raber and 6 more
Open access · bronzeAbstract read
In one paragraphArticle in Molecular cancer research : MCR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 3 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors at 4 institutions in 2 countries.
Rajaa El MeskiniCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland. zweaverohler@mail.nih.gov elmeskinir@mail.nih.gov.
Devon AtkinsonCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland.ORCID 0000-0002-6675-1531 Alan KulagaCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Abdalla AbdelmaksoudCollaborative Bioinformatics Resource (CCBR), Center for Cancer Research (CCR), National Cancer Institute, Bethesda, Maryland.
Michelle GumprechtCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Nathan PateCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland.ORCID 0000-0003-0409-4190 Susana HayesAstraZeneca, Gaithersburg, Maryland.
Michael OberstAstraZeneca, Gaithersburg, Maryland.
Ian M KaplanAdaptive Biotechnologies, Seattle, Washington.
Patrick RaberAdaptive Biotechnologies, Seattle, Washington.
Terry Van DykeMouse Cancer Genetics Program, CCR, NCI/NIH, Frederick, Maryland.
Shyam K SharanCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland.ORCID 0000-0002-9333-870X Robert HollingsworthAstraZeneca, Gaithersburg, Maryland.
Glenn MerlinoLaboratory of Cancer Biology and Genetics, CCR, NCI/NIH, Bethesda, Maryland.
Zoë Weaver OhlerCenter for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland. zweaverohler@mail.nih.gov elmeskinir@mail.nih.gov.ORCID 0000-0002-6287-2504 Frederick National Laboratory for Cancer Research · USAstraZeneca (Japan) · JPCenter for Cancer Research · USAdaptive Biotechnologies (United States) · US
Funding
Preclinical GEM and GDA Models of Primary and Metastatic MelanomaZIABC011738 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHARAN, SHYAM · 2016 to 2025
$14.1MPreclinical Mouse Models for Studying Immune Checkpoint Inhibitor ResponseZIABC011167 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MERLINO, GLENN T. · 2009 to 2024
$12.4MIntramural NIH HHS ZIA BC011738
6 · The paper itselfAbstract
Only a subset of patients responds to immune checkpoint blockade (ICB) in melanoma. A preclinical model recapitulating the clinical activity of ICB would provide a valuable platform for mechanistic studies. We used melanoma tumors arising from an Hgf
Indexed as
AnimalsAntibodies, MonoclonalB7-H1 AntigenBiomarkersCD8-Positive T-LymphocytesDisease Models, AnimalMelanomaMiceReceptors, Antigen, T-CellAntibodies, MonoclonalB7-H1 AntigenBiomarkersCd274 protein, mousedurvalumabReceptors, Antigen, T-Cell
Identifiers
PMID33888600
PMCPMC9533714
OpenAlexW3154074238
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390